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Objective: This study was undertaken to determine the effect of gadolinium arteriography on renal function and its
diagnostic accuracy in patients with azotemia with suspected renovascular disease.
Methods: Catheter-based digital subtraction arteriographic studies with gadolinium as the contrast agent were performed
on 25 occasions in 21 consecutive patients with azotemia to evaluate renal arterial circulation. Gadolinium (gadodiamide,
287 mg/mL) was the only contrast used in these studies. Quantities of gadolinium administered ranged from 40 to 264
mL (mean  standard deviation, 124  74 mL). Serial determinations of renal function were performed in all patients.
Arteriography was undertaken 20 times after prior renal revascularizations: seven times as a routine postoperative
follow-up study, nine for increasing azotemia, three for worsening hypertension, and once for evaluation of a known renal
artery stenosis in patient with an abdominal aortic aneurysm. Three additional arteriograms were performed as part of an
evaluation for suspected renovascular hypertension. The two remaining arteriograms were performed in patients with
known aortic aneurysms in whom renal artery stenosis was suspected.
Results: No adverse changes in renal function followed gadolinium arteriography. Prearteriography serum creatinine
values ranged from 1.6 to 9.1 mg/dL (3.0  1.4 mg/dL), compared with postangiography values that ranged from 1.2
to 8.4 mg/dL (2.9  1.3 mg/dL). Comparable blood urea nitrogen values ranged from 23 to 71 mg/dL (40.1  13.5
mg/dL) before arteriography and from 21 to 68 mg/dL (36.5  13.3 mg/dL) after arteriography. All 38 renal arteries
evaluated were adequately imaged. First-order and second-order branchings were well visualized on selective renal
studies. Twenty-one renal arteries showed no abnormalities, including six of seven reconstructed arteries subjected to
early postoperative evaluation. Twelve renal arteries manifested significant disease, including seven with stenoses and five
that had become occluded. Among five additional renal arteries studied, two exhibited obstructing thrombus, two had
dissections, and one had a kinked aortorenal bypass graft.
Conclusion: Catheter-based arteriography in patients with azotemia with gadolinium as a contrast agent is a safe and
effective means to evaluate the renal arterial circulation. The preferential use of gadolinium in lieu of nephrotoxic
iodinated contrast agents for catheter-based arteriography in patients with azotemia is supported by this experience. (J
Vasc Surg 2003;37:346-52.)
Renovascular hypertension is a well recognized form of
correctable hypertension. However, if benefits are to be
expected after open surgical or endovascular renal revascu-
larization for renal artery stenosis (RAS) in individuals with
azotemia, careful patient selection and adequate imaging of
the renal vasculature is mandatory.
Iodinated contrast arteriography has been the usual
means of evaluating renovascular anatomy, but it carries the
risk of nephrotoxicity, to which patients with preexisting
renal dysfunction are particularly susceptible. In fact, con-
trast nephropathy is the third most common cause of
hospital-acquired renal failure.1 Gadolinium-enhanced
magnetic resonance angiography (MRA) avoids these
nephrotoxic risks, yet it tends to overestimate the severity of
stenoses and provides poor visualization of smaller arteries.
Carbon dioxide (CO2) arteriography also reduces the risk
of nephrotoxicity, but it frequently does not provide ade-
quate images to make definitive clinical decisions. A better
imaging method in patients with azotemia with potential
renovascular disease is needed.
The safety and efficacy of catheter-based gadolinium
arteriography in the evaluation of RAS with gadodiamide as
the sole contrast agent to our knowledge has not been
previously reported. This study reviews a recent arterio-
graphic experience in patients with azotemia in whom renal
artery obstructive disease was either suspected or whose
earlier renal artery revascularization was being evaluated
after surgery. The purpose of this study was to make a
preliminary assessment as to whether, in a small population
of patients with azotemia undergoing arteriography with
gadolinium, images are adequate and renal function, as
assessed with serum creatinine concentration, is preserved
throughout the periprocedural period. It was hypothesized
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that gadolinium contrast arteriography is safe and effective
for use in this high-risk group of patients.
PATIENTS AND METHODS
Twenty-one consecutive patients with azotemia (11
men, 10 women; mean age, 64 years; range, 21 to 82 years)
with suspected or known renovascular disease underwent
25 catheter-based gadolinium arteriographic studies from
September 1998 to December 2001. All patients had renal
insufficiency (mean creatinine level, 3.0  1.4 mg/dL;
range, 1.6 to 9.1). Two patients had solitary kidneys. This
retrospective review study was approved by the University
of Michigan Medical School Institutional Review Board for
Human Subject Research (IRBMED) #1999-591.
Catheter-based renal arteriography was performed with
nondiluted gadolinium contrast (gadodiamide, 287 mg/
mL; Omniscan, Nycomed, Princeton, NJ). Quantities of
gadolinium used ranged from 40 to 264 mL (mean, 124
74 mL). An arteriogram was judged adequate if a stenosis
involving the main renal artery or its primary segmental
branches could be identified or excluded. Serial determina-
tions of renal function were performed in all patients before
and after the arteriographic procedure. All postprocedure
studies were performed between 24 and 48 hours after the
contrast load had been given. Worsening of renal function
was defined as an increase in serum creatinine level of
greater than 0.3 mg/dL. Evaluation of hepatic function
was assessed before and after arteriography with determi-
nation of the patients international normalized ratio (INR)
on 22 occasions and liver enzyme measurements (amino
transaminases, alkaline phosphatase, and bilirubin) on 19
occasions.
Twenty arteriograms were performed after prior revas-
cularizations for RAS, including two patients with previous
percutaneous transluminal angioplasty. Included were nine
arteriograms performed for a suspected renal artery cause of
worsening azotemia, accelerating hypertension in three
patients, routine postoperative studies after renal revascu-
larization in seven patients, and one in a patient with a
known abdominal aortic aneurysm (AAA) and a prior renal
angioplasty. The remaining five arteriograms were per-
formed in patients without history of prior intervention for
RAS but with suspected renovascular disease, including
three obtained as part of the initial investigation for severe
hypertension and two for suspected RAS in patients with
known AAAs.
Three patients underwent more than one arterio-
graphic study. Two patients had preoperative studies fol-
lowed by postoperative studies. One patient had three
arteriograms: first for an initial evaluation, next after revas-
cularization showing a kinked renal artery bypass graft, and
last for reevaluation after reoperation.
Measurements of renal and liver function were sub-
jected to statistical analysis. Paired Student t test was used
to compare continuous variables (blood urea nitrogen,
serum creatinine, INR, bilirubin, aminotransaminases, and
alkaline phosphatase).
RESULTS
No individual patient had an adverse change in renal
function after gadolinium arteriography (Table). The over-
all group’s mean prearteriography blood urea nitrogen of
40.1  13.5 mg/dL (range, 23 to 71 mg/dL) was un-
changed after arteriography, with a value of 36.5  13.3
mg/dL (range, 21 to 68 mg/dL; Fig 1, A). Similarly, the
mean prearteriographic serum creatinine level of 3.0 1.4
mg/dL (range, 1.6 to 9.1 mg/dL) was not altered after
arteriography, with a value of 2.9 1.3 mg/dL (range, 1.2
to 8.4 mg/dL; Fig 1 , B). Liver synthetic function, reflected
in the mean INR, was also unchanged, being 1.1  0.1
before arteriography and 1.1 0.1 postarteriography. The
bilirubin value before arteriography of 0.8  1.0 mg/dL
was not different than the after arteriography value of 0.7
0.6 mg/dL. Similarly, amino transaminases and alkaline
phosphatase levels before arteriography were not signifi-
cantly altered after arteriography.
Among the 38 renal arteries evaluated with gadolinium
alone, all were adequately visualized. Twenty of the 25
studies reported were selective renal angiograms. Twenty-
one renal arteries showed no disease. Twelve renal arteries
had a significant RAS (Fig 2), including five that since the
preoperative studies had progressed to occlusion. First-
order and second-order branches and accessory renal arter-
ies were well visualized with selective renal studies (Fig 3).
Two renal arteries had obstructing thrombus, renal artery
dissections were evident in two arteries, and one renal
artery graft had a kink.
Twenty arteriograms were performed after earlier renal
revascularizations. Nine of these studies were done for
suspected renal artery disease and an elevated serum creat-
inine level (four studies were normal, four had significant
renal artery stenoses, and one revealed bilateral obstructing
renal artery thrombus). Three other studies were obtained
for worsening hypertension (one revealed a significant
RAS, one a renal artery occlusion, one a renal artery dissec-
tion, and one a segmental renal artery occlusion). Six of
seven routine postoperative arteriograms showed patent
reconstructions (Fig 4), and one revealed a kinked aortore-
nal bypass. This latter patient underwent revision of the
bypass with a subsequent normal postoperative arterio-
gram. Arteriography in the patient with a known AAA, who
had undergone an earlier percutaneous renal angioplasty,
revealed occlusion of the renal artery. Another patient who
had undergone a ruptured thoraco-AAA repair had acute
renal failure develop, and arteriography in this case revealed
a stenosis of one renal artery and occlusion of the contralat-
eral renal artery.
Three arteriograms performed for severe hypertension
and suspected RAS revealed bilateral main renal artery
occlusions in one patient, a significant stenosis in the sec-
ond study, and a dissection in the third arteriogram. Gad-
olinium arteriography performed in two patients for evalu-
ation of AAA with suspected renal artery disease showed a
renal artery occlusion in one patient and bilateral stenosis in
the second.
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DISCUSSION
The ability to evaluate patients with azotemia for renal
artery disease without the risk of nephrotoxicity related to
contrast toxicity might allow for a more aggressive diagnos-
tic approach in those suspected to have correctable reno-
vascular hypertension and reversible ischemic nephropathy.
It is well recognized that untreated RAS results in an
increasing need for antihypertensive medications and a
worsening of renal function, which may culminate in end
stage renal failure.2-4 Appropriate open surgical or cathe-
ter-directed treatment of RAS requires careful selection of
patients on the basis of certain physiologic and anatomic
criteria. Therapeutic benefits are anticipated in 75% to 85%
of patients regarding improved control of hyperten-
sion.5-11 Improvement of kidney function in patients with
severe renal insufficiency may occur but is more controver-
sial and less well defined.12,13
Optimal performance of a renal revascularization pro-
cedure requires adequate imaging of the renal vessels. In
patients with normal renal function, the risk of contrast
nephropathy with standard iodinated contrast media is
extremely low. However, in the setting of preexisting renal
dysfunction, an elevation of serum creatinine level occurs in
15% to 22% of patients after arteriography.14,15 Patients
with diabetic nephropathy, which was the case in two of our
patients, are at even higher risk for contrast nephrotoxici-
ty.16,17
The exact risk of contrast nephropathy in patients with
azotemia with RAS has not been established. However,
substantial creatinine elevations were observed in 23% of
patients with moderate renal insufficiency (baseline serum
creatinine value, 1.6 to 3.9 mg/dL) undergoing renal
arteriography with or without percutaneous revasculariza-
tion.18 Other investigators have reported acute renal insuf-
ficiency in 26% of those undergoing percutaneous renal
angioplasty with conventional contrast agents.19
Alternative means of imaging renal arteries, especially
in patients with azotemia, have been sought, but most have
shortcomings. MRA has replaced iodinated contrast an-
giography in many practices because of the lower nephro-
toxic risk. Although its use to document RAS is well recog-
nized, MRA often overestimates the degree of stenosis and
may not adequately image accessory or small distal renal
arteries.20-26 CO2 arteriography provides a second contrast
agent with lesser nephrotoxic risks, although it may over-
estimate stenoses from underfilling and bowel gas arti-
fact.18,27 Furthermore, repeat aortic injections of CO2 may
lead to accumulation of this gas in mesenteric vessels with
subsequent abdominal pain, intestinal ischemia, and infarc-
tion.28
Gadolinium catheter-based arteriography in patients with azotemia
Patient
Age/
gender Study Basis for arteriographic study Arteriographic findings
Blood urea
nitrogen value
before/after
arteriography
(mg/dL)
Serum creatinine
value before/after
arteriography
(mg/dL)
1 67F 1 ARB and contralateral Nx, Incr RI ARB patent 46/41 3.5/3.1
2 66M 2 HRB and contralateral Nx, Incr RI HRB stenotic 23/21 3.3/2.9
3 HRB, POA HRB patent 25/41 3.1/3.4
3 62M 4 ARB, Incr RI ARB patent 53/48 4.4/4.1
4 21M 5 IRB, Incr Htn IRB patent 26/21 2.4/2.4
5 60F 6 RAEA and contralateral Nx, Incr RI RAEA patent 32/25 3.7/3.5
6 71F 7 ARB and contralateral Nx, Incr RI ARB patent 25/27 2.3/1.9
7 77F 8 RAI, Htn RAS 32/29 2.0/1.9
8 64M 9 Iliac endarterectomy, (prior IRB), POA IRB patent 30/28 3.7/2.5
9 58M 10 Ruptured TAAA, Incr RI RAO, contralateral RAS 51/63 3.1/3.4
10 67M 11 RPTA, Htn RPTA dissection and RAO 40/39 1.7/1.7
11 59F 12 HRB and contralateral Nx, Incr RI HRB patent 62/68 2.9/3.1
12 67F 13 AAA, suspected RAS Unilateral RAS 34/23 1.8/1.6
13 44F 14 Malignant Htn, suspected RAS Unilateral renal artery dissection 56/43 3.3/2.9
15 ARB, POA ARB kink 33/29 3.6/2.9
16 ARB (revised), POA ARB patent 26/25 3.2/3.4
14 79M 17 AAA, suspected RAS Unilateral RAO 33/27 2.4/2.4
15 63M 18 IRB, Incr RI IRB thrombus, contralateral
RAS (thrombus)
71/66 9.1/8.4
16 82F 19 IRB, Incr RI IRB patent, contralateral RAS 61/37 1.6/1.2
17 50M 20 Malignant Htn Bilateral RAO 32/32 2.1/2.1
21 ARB and contralateral RAI, POA ARB and RAI patent 45/36 1.8/1.8
18 75F 22 RAS, Incr RI Unilateral RAS 39/44 2.8/3.1
19 66M 23 AAA, suspected RAS Bilateral RAS 41/28 1.9/2.0
20 67F 24 RAS, Incr RI Unilateral RAS 55/40 3.2/3.2
21 78M 25 IRB, POA IRB patent 46/43 2.7/2.5
ARB, Aortorenal bypass; HRB, hepatorenal bypass; IRB, iliorenal bypass; RAI, renal artery reimplantation; RAEA, renal artery endarterectomy; RPTA, renal
artery percutaneous arterioplasty; Nx, nephrectomy; RAS, renal artery stenosis; RAO, renal artery occlusion; Htn, hypertension; TAAA, thoraco-AAA; Incr
RI, increasing renal insufficiency; POA, (routine) postoperative arteriogram.
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Preangiographic administration of acetylcysteine is a
potential pharmacologic means of decreasing the nephro-
toxicity of nonionic, low osmolality iodinated contrast.29
Oral acetylcysteine and hydration compared with a placebo
reduced nephrotoxicity from 21% to 2% in one group of
patients with azotemia undergoing computed tomography
with intravenous contrast.29 Whether acetylcysteine might
be protective in patients with azotemia undergoing arte-
riography for suspected RAS is unknown.
Catheter-based arteriographic use of gadolinium has
been advocated as an adjunct to arteriography with CO2
30
in renal arteries,18,31,32 distal extremity arteries,33,34 arte-
riovenous fistulas35,36 carotid arteries,37,38 the thoracic
arch and great vessels,39 and for placement of TIPS
shunts.40 Gadolinium-based arteriography alone has also
been advocated for evaluation of the renal circulation in
kidney transplant recipients.41 Despite these many reports
and the fact that the safety of gadolinium-based contrast
appears well documented in patients with renal insufficien-
cy,31,42 studies on catheter-based gadolinium arteriogra-
phy alone in the evaluation and follow-up of patients with
renovascular disease and renal insufficiency have only been
reported in four patients.43,44
Fig 3. Demonstration of first-order and second-order renal artery
branchings and their communicating collaterals with selective in-
jection of small renal main renal artery in patient with multiple
obstructions.
Fig 1. A, Preangiogram and corresponding postangiogram se-
rum creatinine values for each patient. B, Preangiogram and cor-
responding postangiogram serum blood urea nitrogen values for
each patient.
Fig 2. Gadolinium arteriographic evidence of proximal left RAS
(arrow) in patient with aortic aneurysm.
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Gadodiamide is a gadolinium-based nonionic com-
pound with an osmolarity of 789 mOsm/kg of water. It is
known to be nontoxic in doses of 0.3 to 0.4 mmol/kg.45-48
Toxicity, when it occurs, follows dissociation of the gado-
linium compound into the Gd3 ion.49 The median lethal
dose of intravenous gadolinium in rats is 10 mmol/kg for
gadolinium diethyltriaminepentaacetic acid,50 and the me-
dian lethal dose of gadodiamide is 38.3 mmol/kg.50,51 The
maximum tolerable dose for gadolinium in humans is un-
known. In this clinical experience, patients often received
greater than 0.4 mmol/kg of gadodiamide without recog-
nized adverse effects. Gadodiamide is cleared through glo-
merular filtration even in the setting of renal insufficien-
cy.52 With normal renal function, the half-life of
gadolinium is 78 minutes. Its half-life increases to 5.8 hours
in moderate azotemia and up to 30 hours in renal failure.53
In a review of approximately 15,000 patients, gadolin-
ium MRA was performed in patients with renal insuffi-
ciency or renal failure without any major adverse effect.47
Gadolinium doses average 20 mL for such MRA studies in
contrast to the mean 124 mL used in this experience. It
appears to be well tolerated. Nevertheless, adverse effects of
gadolinium-based contrast agents have been reported, in-
cluding nausea, headache, and dizziness in up to 3% of
patients. Intravenous administration of gadolinium dieth-
yltriaminepentaacetic acid has resulted in asymptomatic
increases in serum iron and bilirubin in 1% to 3% of patients,
suggesting hemolysis, albeit clinically insignificant.54 In
Fig 4. Gadolinium arteriographic documentations of: A, patent saphenous vein hepatorenal bypass with selective
celiac artery injection; B, aortogram documenting patent saphenous aortorenal bypass; and C, patent main renal artery
after percutaneous transluminal angioplasty with stent placement.
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this series, no significant changes were seen in liver enzymes
or the liver’s synthetic function. Although they were not
used in this experience, high osmolarity gadolinium agents,
such as gadopentetate dimeglumine (1960 mOsm/kg wa-
ter), cause peripheral pain during injection, whereas lower
osmolarity agents, such as gadodiamide, cause less discom-
fort.
Marked changes in renal function have rarely been
reported after the arteriographic use of gadolinium.55 Al-
though a significant increase in serum creatinine level after
intraarterial administration of gadodiamide was reported in
a patient with renal transplant, this individual subsequently
had biopsy confirmation of acute and chronic rejection.18
In our experience, no patient had an adverse effect on renal
function after gadolinium arteriography.
Preferential use of gadolinium for all arteriographic
studies is not advocated. The intraarterial use of relatively
large volumes of gadolinium described in our experience
has not received US Food and Drug Administration ap-
proval. However, evaluation of the renal circulation in
patients with azotemia warrants avoidance of nephrotoxic
contrast agents that might prove to be renal, and possibly
life, threatening. Gadolinium catheter-based arteriography
in this setting produces good quality images sufficient for
evaluation of renovascular disease and appears safe for
compassionate use in patients with renal dysfunction.
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